Cancer, metabolic health, and peptides: what the research shows

This article is educational. Nothing here suggests any peptide treats, prevents, or diagnoses cancer. If you have active cancer or a history of it, that is a reason to discuss any metabolic or growth-pathway peptide with your oncologist before using it, not a footnote to skip past.

The relationship between metabolic health and cancer risk is one of the better-established areas of cancer epidemiology. According to the National Cancer Institute and the International Agency for Research on Cancer, excess body weight is associated with increased risk of at least 13 cancer types, including cancers of the breast (in postmenopausal women), colon and rectum, endometrium, esophagus, kidney, liver, and pancreas. The proposed mechanisms include chronic low-grade inflammation, elevated circulating insulin and insulin-like growth factor 1 (IGF-1), altered signaling from fat tissue (adipokines like leptin and adiponectin), and increased oxidative stress. Improving metabolic health through sustained weight management, physical activity, and dietary change is associated with lower cancer risk in large population studies. That association is well established; what happens when a specific pharmacological intervention is layered on top is a separate, more complicated question.

Here is where the picture gets more complex. GLP-1 receptor agonists, such as semaglutide and tirzepatide, produce substantial weight loss and improve insulin sensitivity in large randomized trials, which would be expected to reduce obesity-associated cancer risk over time. At the same time, rodent studies found that semaglutide caused thyroid C-cell tumors in rats and mice at clinically relevant exposures, driven by GLP-1 receptor activation on rodent thyroid C-cells, a receptor distribution that differs from that in humans. Because of this rodent finding, the FDA required a boxed warning about thyroid C-cell tumor risk and contraindicated use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Large post-marketing surveillance and pharmacovigilance data in humans have not shown a clear signal of increased medullary thyroid cancer to date, but the FDA and manufacturers continue post-marketing monitoring, and the rodent signal is why the warning exists at all.

Growth hormone secretagogues, a category that includes GHRP-family peptides and GHRH analogs like CJC-1295, raise circulating IGF-1, which is one of the primary downstream signals of growth hormone activity. IGF-1 promotes cell proliferation and inhibits programmed cell death (apoptosis) as part of its normal physiological role in growth and tissue repair. Multiple epidemiological studies, including a widely cited pooled analysis published in The Lancet, have found that higher circulating IGF-1 within the normal range is associated with modestly increased risk of certain cancers, including breast, prostate, and colorectal cancer. This is observational, correlational evidence; it does not establish that elevating IGF-1 through a growth hormone secretagogue causes cancer to develop. It does establish a biologically plausible mechanism by which sustained IGF-1 elevation could, in theory, support the growth of an existing but undiagnosed early-stage cancer, which is a meaningfully different and much narrower claim.

BPC-157 promotes angiogenesis, the formation of new blood vessels, which is part of why it has been studied in animal models of tissue healing. Angiogenesis is also a necessary process for solid tumors to grow beyond a few millimeters in size, which is the biological basis for an entire class of approved cancer drugs (angiogenesis inhibitors) that work by blocking this exact process. Direct research on BPC-157 specifically in the context of cancer risk is sparse; a 2025 systematic review of BPC-157 research for orthopaedic applications found only one qualifying human clinical study out of 544 screened, with the rest being preclinical animal work, and essentially none of that research was designed to look at tumor promotion. The absence of a documented cancer signal here reflects an absence of research attention, not evidence of safety.

The broader limitation across this entire topic is that most compounds sold as research peptides have never been systematically tested in cancer models, in humans or animals. Mechanisms like IGF-1 elevation, angiogenesis promotion, and immune modulation are all biologically plausible pathways by which a compound could theoretically influence the growth of an undetected cancer, but plausibility is not the same as demonstrated effect, and there is no substitute for actual data that doesn't yet exist.

Evidence quality: the link between obesity and cancer risk is supported by strong human evidence from large epidemiological studies. The cardiovascular benefit of FDA-approved GLP-1 agonists like semaglutide is supported by strong human evidence, most notably the SELECT trial, a large randomized controlled trial published in the New England Journal of Medicine in 2023, which found reduced major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity. The IGF-1/cancer risk association is moderate human evidence from observational epidemiology, not interventional trial data. The cancer-relevance of BPC-157's angiogenic effects, and of growth hormone secretagogues more specifically, is mechanistic research and mostly animal data, with essentially no direct human cancer-outcome studies.

Practically, the distinction that matters most is between FDA-approved, extensively studied drugs like semaglutide, which carry large-scale human safety data, defined manufacturing standards, and active post-marketing surveillance, and unregulated research compounds sold without any of that infrastructure. Conflating the two, treating an unregulated GHRP or an unstudied healing peptide as if it carries the same safety evidence as an approved drug, misrepresents what is actually known. For anyone with a personal or family history of cancer, or any undiagnosed symptoms that could indicate an underlying condition, the presence of plausible growth-promoting or angiogenic mechanisms in a given peptide is a reason for that conversation to happen with an oncologist before use, not after.

It's also worth being precise about what "screened for cancer" typically does and doesn't mean in a research protocol. Most clinical trials of metabolic peptides, GLP-1 agonists included, exclude participants with active cancer or a recent cancer history at enrollment, and they track cancer-related adverse events reported during the trial period, but a multi-year trial is not designed or powered to detect a small increase in cancer incidence that might only become apparent over a much longer follow-up window, since cancer can take years to become clinically detectable after any biological process that might contribute to its growth. This is a structural limitation of how these trials are built, not a flaw specific to any one compound, and it's part of why regulatory agencies keep monitoring drugs after approval rather than considering the question closed once a trial concludes.

The IGF-1 and cancer risk literature also deserves a caveat about what "associated with increased risk" means in an epidemiological analysis. The Renehan meta-analysis and similar studies compare cancer incidence across people with naturally different IGF-1 levels within the general population; they are not experiments where IGF-1 was deliberately raised in some participants and not others. That design can detect a correlation but cannot, on its own, rule out the possibility that some other factor correlated with both higher IGF-1 and cancer risk (for instance, certain patterns of diet, body composition, or genetics) is doing some or all of the work. This is a standard limitation of observational epidemiology, and it's one reason the finding is described here as an association worth taking seriously rather than as proof that raising IGF-1 through a secretagogue causes cancer.

Taken together, the state of the research supports a fairly narrow and specific conclusion: established metabolic interventions with strong human trial data, like approved GLP-1 agonists, have a well-characterized benefit-risk profile that includes a specific, monitored cancer-related warning; and compounds that raise IGF-1 or promote angiogenesis carry a biologically plausible, but not directly proven in humans, reason for added caution in anyone with current or recent cancer. That is meaningfully different from either extreme, claiming these peptides cause cancer, or claiming the cancer connection is overblown, and the more precise, hedged version is the one supported by what has actually been studied.